Dorsey Wright & Associates cut its stake in shares of Relx Plc (NYSE:RELX - Free Report) by 22.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 63,028 shares of the technology company's stock after selling 18,231 shares during the quarter. Dorsey Wright & Associates' holdings in Relx were worth $2,863,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Private Trust Co. NA increased its holdings in Relx by 19.2% in the 4th quarter. Private Trust Co. NA now owns 1,237 shares of the technology company's stock worth $56,000 after buying an additional 199 shares in the last quarter. Sage Mountain Advisors LLC increased its holdings in Relx by 5.1% in the 4th quarter. Sage Mountain Advisors LLC now owns 5,292 shares of the technology company's stock worth $240,000 after acquiring an additional 258 shares in the last quarter. Peapack Gladstone Financial Corp raised its position in shares of Relx by 5.7% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 4,924 shares of the technology company's stock valued at $234,000 after purchasing an additional 267 shares during the period. EWA LLC boosted its holdings in Relx by 5.2% in the 3rd quarter. EWA LLC now owns 5,501 shares of the technology company's stock worth $253,000 after buying an additional 272 shares during the period. Finally, Marks Group Wealth Management Inc raised its holdings in Relx by 1.3% during the fourth quarter. Marks Group Wealth Management Inc now owns 26,196 shares of the technology company's stock valued at $1,190,000 after acquiring an additional 325 shares during the period. Hedge funds and other institutional investors own 15.02% of the company's stock.
Analysts Set New Price Targets
RELX has been the subject of several research analyst reports. Barclays upgraded Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. Redburn Atlantic began coverage on shares of Relx in a research report on Wednesday, January 8th. They set a "buy" rating on the stock. StockNews.com downgraded shares of Relx from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group assumed coverage on shares of Relx in a research note on Wednesday, March 26th. They set a "buy" rating for the company. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy".
Check Out Our Latest Research Report on Relx
Relx Price Performance
Relx stock traded up $0.26 during midday trading on Tuesday, reaching $50.67. 402,553 shares of the stock traded hands, compared to its average volume of 754,693. The company has a quick ratio of 0.47, a current ratio of 0.52 and a debt-to-equity ratio of 1.46. Relx Plc has a 12 month low of $40.25 and a 12 month high of $51.99. The stock's fifty day moving average is $49.53 and its 200-day moving average is $47.84. The stock has a market cap of $94.05 billion, a P/E ratio of 27.24, a PEG ratio of 2.73 and a beta of 0.90.
Relx Increases Dividend
The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be issued a $0.5586 dividend. The ex-dividend date is Friday, May 9th. This is a positive change from Relx's previous semi-annual dividend of $0.23. This represents a dividend yield of 1.6%. Relx's dividend payout ratio (DPR) is 59.68%.
Relx Company Profile
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Featured Articles
Before you consider Relx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.
While Relx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
